Mechanisms and Interventions of Treatment-Resistant Schizophrenia Based on Brain Organoids
Key facts
- Who runs it
- Shanghai Mental Health Center
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 10 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Record updated
- 17 November 2026
Who can take part
- Sex
- Women and men
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Meet the DSM-5 diagnostic criteria for schizophrenia
- Meets the diagnostic criteria for early-onset schizophrenia (age of onset < 18 years)
- Meet the diagnostic criteria for treatment-resistant schizophrenia, defined as:; Inadequate response from adequate trials of two different classes of antipsychotic drugs (≥ 600 mg/day chlorpromazine equivalents), at least 6 weeks; Persistence of positive symptoms,defined as a score of ≥ 4 on at least two items, or a score of ≥ 6 on at least one item, of the positive subscale of the PANSS; At least moderate functional impairment, as indicated by a PSP score ≤ 70
- Written informed consent
Who cannot take part
- Current or past neurological illness, severe physical diseases, substance abuse or alcohol dependence, mental retardation, pregnant or lactation
- Uncooperative or risky patients with high excitement, stupor, disorder of words and deeds, negative suicide, etc
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Approximately 20-30% of patients with schizophrenia show poor response to standard antipsychotic medications, which is defined as treatment- resistant schizophrenia (TRS), yet the underlying pathological mechanisms remain largely unknown. Brain organoids, also referred to as cerebral organoids, have emerged as a promising tool for modeling neurodevelopmental disorders in the laboratory. In this observational study, blood samples will be collected from TRS patients and their family members to generate personalized brain organoids. This study aims to elucidate the mechanisms of TRS and to provide preclinical evidence for developing personalized intervention strategies.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 November 2026